Table 6.
Clinical characteristics of patients with HCV reactivation
| Treatment arm | Age/sex | HCV antibody | HCV RNA at baseline (U/mL) | HCV RNA post-baseline (U/mL) | Time to onset of HCV reactivation | ALT increasea | Antiviral treatment | PD |
|---|---|---|---|---|---|---|---|---|
| Atezo + bev | 64/M | Positive | 4.5 | 250,000 | Day 58 | No | No | No |
|
| ||||||||
| Atezo + bev | 77/F | Negative | Not available | 180,000 | Day 273 | No | No | No |
|
| ||||||||
| Atezo + bev | 47/M | Positive | 159,000 | 2,064,846 | Day 175 | No | No | No |
|
| ||||||||
| Atezo + bev | 53/M | Negative | <15 | 260,000 | Day 160 | No | No | No |
|
| ||||||||
| Atezo + bev | 53/M | Positive | Not available | 25 | Day 89 | No | No | No |
|
| ||||||||
| Atezo + bev | 52/M | Positive | 61,800 | 4,300,000 | Day 169 | No | No | No |
|
| ||||||||
| Sorafenib | 81/M | Positive | 11 | 2,464,675 | Day 89 | No | No | PD at Day 81 |
|
| ||||||||
| Sorafenib | 64/M | Positive | 2,800 | 49,000 | Day 170 | Yes (ALT was 46.2 U/L at baseline; ALT was 181 U/L on Day 105) | No | PD at Day 168 |
|
| ||||||||
| Sorafenib | 81/M | Positive | 7,070 | 4,830,000 | Day 97 | ALT was 192 U/L at Day 57, but was normal at Day 97 | No | PD at Day 86 |
ALT, alanine aminotransferase; atezo, atezolizumab; bev, bevacizumab; HBsAg, hepatitis B surface antigen; PD, patient discontinuation; U, units.
a
Greater than 3-fold increase from baseline and >100 U/L at any time point.